Dr Prescott will also tell academic and business delegates at the White Rose Bioscience Forum in York today (31 October), that whilst venture capitalists (VCs) have their eye on the potential high returns of such an emergent market, they will remain wary of investing until key broader issues such as legal, regulatory and intellectual property complexities have been resolved.
For young companies, a major hurdle is a lack of support from the pharmaceutical industry for cell-based therapeutic product development. “Traditionally, pharma have supported products coming through the biotech industry through licensing and partnering, providing support for clinical trials, financing and expertise,” says Dr Prescott. “But this is generally not the case here; they are tending to support enabling technologies and research-based reagents and tools instead.”
According to Dr Prescott, the reticence to support cell-based therapy development is because the end product will usually be tailored to the individual patient, with delivery within a clinical setting, administered by specialists. “This requires a very different business model from that of traditional high volume distribution of drugs routinely available to the patient,” she says.
She continues: “If that crucial support is not there from the pharma industry, young companies need to think very hard about whether they realistically have the expertise to take a product to market on their own.”
There’s not much good news in terms of funding available to young companies either, says Dr Prescott: “There’s simply less seed and early stage money to go round at the moment. Investment trends across Europe show a general decline in VC activity, and of the money invested, the majority of it is used to continue to support the more mature biotech companies. In addition, this may also impact on the ability of early stage companies to raise match funding required by many Government grant schemes.”
For VCs, patent issues are also a major cause for concern with dominating patents already granted covering methods of isolating, cultivating, differentiating and delivering stem cell lines. “Young companies need to be very careful that they have the freedom to operate, and where they need to buy-in technology, commercial licenses can cost as much as $100k, which is out of the range of most younger biotech companies, “ says Dr Prescott.
“VCs are also wary that for the embryonic stem cell-based products, the European market may remain fragmented despite the proposal for an EU-wide regulatory framework for advanced stem cell therapies published by the Commission for EU Communities. The proposal respects national confidence on the use of stem cells. This means that a product approved for launch in the UK may need work to be approved in other EU countries, which impacts on cost and time.” she explains.
“I appreciate that this is a hard message, but it’s a tough climate. The most pragmatic advice I can give to young companies is to show venture capitalists that they have anticipated, understood and determined a route forward to resolve key hurdles facing them,” she says. “This will underpin the success of UK biotech companies whose technology expertise lies in stem cell therapeutics.”
Jo Kelly | alfa
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences